| abstract |
Compounds are provided that act as antagonists of potent CCR9 receptors. Animal tests demonstrate that these compounds are useful for treating inflammation, a characteristic disease for CCR9. The compounds are generally aryl sulfonamide derivatives and are useful in pharmaceutical compositions, methods of treating CCR9-mediated diseases, and as controls in tests for the identification of CCR9 antagonists. |